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ophthalmology and neurology departments was especially studied. The pharma-
coeconomic evaluation was performed using a direct cost comparison analysis, in 
which MAbs cost is compared (2011-2014) to total drug cost per department, total 
in-patent drug cost, in-patent antibiotics cost and anti-HIV drug cost. The cost sav-
ing of Central Cytostatic Drug Preparation Unit operation for the year 2014 was 
especially studied. The analysis was performed in Euros (€ ) and drug cost was based 
on average hospital prices in Greece (official price lists). Results: Data analysis 
revealed that MAbs relative cost showed an augmentative trend throughout the 
study period (from 12.6%, 2008 to 13.45%, 2014). MAbs cost for all studied clin-
ics, with the exception of ophthalmology and hematology departments, showed 
minor decline. In-patent antibiotics and anti-HIV drugs represented a substantial 
and ongoing category of cost burden prescribed drugs (from 6.18%, 2011 to 9.98%, 
2014 and from 13.04%, 2011 to 21.44%, 2014 respectively). ConClusions: From 
2008 to 2012, though a substantial reduce of hospital pharmaceutical expenditure 
was obtained, due to memorandum obligations, an increase in MAbs consumption 
was detected (from 12.6% to 13.45%of total drug cost).The average hospital prices 
for all drugs were reduced for the same period. The total cost saving is mainly due 
both to generics and off-patent drugs use and drugs’ price negotiations supported 
with an obligated by the Ministry of Health 5% and 6.5 % rebate for in-patent drugs.
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objeCtives: In a randomized, double blind, controlled phase IV trial 
(ADACTA)*,Tocilizumab (TCZ) demonstrated superiority vs Adalimumab (ADA) in 
monotherapy, reducing signs and symptoms of rheumatoid arthritis (RA) in patients 
by whom methotrexate (MTX) is not tolerated or for whom it is inappropriate.The 
aim of this analysis was to evaluate the cost per response and the cost per disease 
remission of TCZ vs ADA in an RA monotherapy setting from the Italian Hospital 
perspective. Methods: TCZ-IV (intra-venous-8mg/kg monthly) and ADA-SC (sub-
cutaneous-40mgQ2W) monotherapy were compared, using efficacy results from 
ADACTA trial, in terms of cost per response (American College of Rheumatology-
ACR20-50-70) and cost per remission for both Disease-Activity-Score (DAS28< 2.6) 
and Clinical-Disease-Activity-Index (CDAI≤ 2.8). Treatment costs were considered 
(drug acquisition, administration and monitoring), obtained from published sources. 
Drug acquisition cost was derived from the ex-factory price. Drug administration 
cost (TCZ-IV only) was based on the cost for nursing and medical staff required for 
each infusion; monitoring visits and tests were considered as one per month for 
TCZ-IV and one every three months for ADA-SC.The analysis was conducted from 
the Hospital perspective and the time horizon was 24 weeks. Results: Compared 
with ADA, TCZ resulted dominant (more effective and less costly). The cost per 
response was lower with TCZ than with ADA: ACR20: € 10,494.5 and € 12,533.4;ACR50: 
€ 14,452.2 vs € 22,271.5;ACR70: € 20,989.1 and € 34,589.3 respectively. The cost per 
remission was € 17,096.4 vs € 58,966.6 for DAS28< 2.6 and € 39,659.6 vs € 66,575.2 for 
CDAI≤ 2.8 for TCZ vs ADA respectively. ConClusions: According to this analysis, 
in Italy TCZ monotherapy can be considered as an efficient strategy compared to 
ADA for treating RA patients intolerant to MTX or for whom MTX is inappropri-
ate. *Gabay C,Emery P,van Vollenhoven R,Dikranian A,Alten R,Pavelka K,Klearman 
M,Musselman D,Agarwal S,Green J,Kavanaugh A; ADACTA Study Investigators.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of 
rheumatoid arthritis (ADACTA):a randomised,double-blind,controlled phase 4 trial. 
Lancet 2013;381(9877):1541-50
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objeCtives: Gout is a urate crystal deposition disease caused by chronic high serum 
uric acid (sUA) levels (i.e., hyperuricemia), resulting in painful flares and tophi. 
Treatment guidelines recommend maintenance of sUA levels < 6 mg/dL; however, 
sUA often remains elevated because of lack of, or inadequate response to therapy. Our 
goal was to understand the relationship between gout control and economic burden 
and to explore the impact of comorbidities. Methods: Data are from the combined 
2012 and 2013 US National Health and Wellness Survey (NHWS), a representative, 
cross-sectional general health survey (2012, n= 71,157; 2013, n= 75,000) of which 3729 
individuals self-reported a gout diagnosis (n= 344 controlled [sUA ≤ 6 mg/dL and 
no flares in past year], n= 2215 uncontrolled [sUA> 6 and/or ≥ 1 flare], and n= 1170 
unknown). Estimated total cost was calculated by adding direct cost (e.g., resource use) 
and indirect cost (e.g., work productivity loss). Those with gout + comorbidities (e.g., 
cardiovascular disease [CVD]) and their relationship with total cost were also exam-
ined. Multivariable generalized linear models were used to control for demographic 
and health characteristics to assess unique burden of uncontrolled gout. Results: 
Adjusted models indicate that those with controlled gout do not statistically differ 
from non-gout subjects. Those with uncontrolled gout reported significantly higher 
total annualized costs than non-gout subjects. Although uncontrolled gout had higher 
total cost than controlled gout, the difference was not significant. Similar patterns 
were observed for gout control and comorbidities. Those with uncontrolled gout + 
comorbidity (diabetes or CVD) reported higher total costs than those without gout or 
their respective comorbidity. There was no statistical difference for those with con-
trolled gout + comorbidity versus those without gout or comorbidity. ConClusions: 
Uncontrolled gout results in higher total costs than for non-gout patients. Controlled 
gout patients have lesser burden—closer to non-gout subjects. Total cost for uncon-
trolled gout may be further exacerbated by comorbidities.
perspective. Results: The difference in cost per response between the alternatives 
was in favor of tocilizumab in all three scenarios examined. In more detail, the 
savings generated by the use of tocilizumab associated with achieving ACR 70 for a 
68kg (mean weight) patient were € 12,529, € 9,657 and € 8,810 from the hospital, health 
system and society’s perspective, respectively. Similarly, the savings regarding DAS 
28≤ 3.2 were € 14,838, € 13,041 and € 12,506 for each perspective respectively. In the 
third scenario (DAS 28< 2.6) the difference in cost per response between tocilizumab 
and adalimumab was € -32,811 from the hospital’s, € -30,522 from the health system’s 
and € -29,831 from the society’s perspective. Results indicate that treating patients 
with tocilizumab IV yields sufficient savings to initiate more patients in treatment 
with tocilizumab in 1L monotherapy and to achieve low disease activity or remission 
with greater probability and less resources. ConClusions: Choosing tocilizumab 
instead of adalimumab as a 1L monotherapy for the RA treatment could be proven 
to be a cost-saving option, with increased significance in the current economic 
environment of restricted healthcare resources and significant budget constraints.
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objeCtives: Non-steroidal anti-inflammatory drugs (NSAIDs) increase vascular 
and gastrointestinal risks. These risks have not been described with chondroitin 
sulphate (CS). This study aims to evaluate the economic impact of osteoarthri-
tis (OA) treatment with CS versus NSAIDs for the Public Healthcare System in 
Catalonia (Spain). Methods: An economic model was developed to estimate the 
health and economic impact of ethical CS prescription due to the avoidance of gas-
trointestinal adverse events (GIAE) and coronary ischemic events (CIE) associated 
with NSAIDs. The estimated population with knee and hands OA was calculated 
from EPISER study, population official data (age ≥ 20 years) and a population-based 
drug utilization study in patients with OA. The annual probabilities of suffer-
ing GIAE and CIE with CS and NSAIDs were obtained from a systematic review 
of medical literature, published meta-analysis and previous economical study 
(VECTRA). Direct healthcare costs (€ 2015) included drug acquisition, GIAE and 
CIE management. Other adverse events associated with NSAIDs with economic 
impact (renal failure, ischemic stroke, liver failure) were not considered in the 
model. Deterministic sensitivity analyses of the extreme values of all variables 
were undertaken. Results: It is estimated that each year 300,000 and 72,000 OA 
patients are treated with NSAIDs and CS, respectively, in Catalonia with a cost of 
11 and 4 million euros. Because 72,000 OA patients are treated with CS instead 
of NSAIDs, 19,222 mild-moderate and 649 severe episodes of NSAID-related GIAE 
and 39 CIE episodes would be avoided annually. The annual savings by avoiding 
GIAE and CIE episodes is estimated at 6.2 million euros and € 493,000, respectively. 
Sensitivity analyzes confirmed the robustness of the results. ConClusions: OA 
treatment with chondroitin sulphate could reduce the health care costs for the 
Public Healthcare System due to the decreased rate of gastrointestinal and car-
diovascular adverse events compared with NSAIDs.
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objeCtives: Pain after arthroplasty is a common condition which can result in 
loss of quality of life and significant financial burden. This study aims to evaluate 
extended-release oxycodone versus morphine in an “if necessary” regime in the 
management of pain post-arthroplasty, from the Brazilian public and private health-
care systems perspectives. Methods: A decision model was developed to analyze 
two scenarios. In both, patients in group 1 received extended-release oxycodone 
and immediate-release opioid. Regarding group 2, in scenario 1, patients received 
immediate-release opioid and, in scenario 2, immediate-release opioid and placebo. 
Efficacy data were obtained from Beer et al., 2005 (scenario 1) and Cheville et al., 2001 
(scenario 2). Direct costs were obtained from official prices lists. In scenario 1, time 
horizon was related to a 3-week treatment period and, in scenario 2, determined by 
the hospitalization period. Discount rates were not applied. Univariate sensitivity 
analysis was performed to evaluate different hospital categories. Results: Total 
costs from the public perspective were 1,486 BRL and 1,520 BRL per patient treated 
in scenario 1, and 3,299 BRL and 3,591 BRL per patient treated in scenario 2, in groups 
1 and 2, respectively. From the private perspective, total costs in scenario 1 were 
3,132 BRL and 3,457 BRL per patient treated and 7,197 BRL and 8,181 BRL per patient 
treated in scenario 2, in groups 1 and 2, respectively. In the univariate sensitivity 
analysis, all evaluated scenarios remained consistent and favorable to the use of 
extended-release oxycodone. ConClusions: The inclusion of extended-release 
oxycodone can result in reduction of hospitalization costs, which would lead to 
resource savings for the payer.
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objeCtives: To assess the cost of monoclonal antibodies in an Athens/Greece ter-
tiary hospital in a seven year cost comparison analysis and to compare results to 
other in-patent drug categories. Methods: In this study (2008-2014) monoclonal 
antibodies (MAbs) consumption in Evaggelismos hospital (931-beds) was assessed. 
MAbs consumption/cost in hematology, oncology, rheumatology, gastroenterology, 
